Focused On-demand Library for N-alpha-acetyltransferase 15, NatA auxiliary subunit

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.

Our library distinguishes itself through several key aspects:

The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.

partner

Reaxense

upacc

Q9BXJ9

UPID:

NAA15_HUMAN

Alternative names:

Gastric cancer antigen Ga19; N-terminal acetyltransferase; NMDA receptor-regulated protein 1; Protein tubedown-1; Tbdn100

Alternative UPACC:

Q9BXJ9; D3DNY6; Q52LG9; Q8IWH4; Q8NEV2; Q9H8P6

Background:

N-alpha-acetyltransferase 15, NatA auxiliary subunit, known by alternative names such as Gastric cancer antigen Ga19 and Protein tubedown-1, plays a crucial role in cellular processes. It functions as an auxiliary subunit of N-terminal acetyltransferase complexes, influencing alpha (N-terminal) acetyltransferase activity. This activity is vital for the growth and development of vascular, hematopoietic, and neuronal systems. Additionally, it is involved in controlling retinal neovascularization and up-regulating transcription from the osteocalcin promoter in complex with XRCC6 and XRCC5.

Therapeutic significance:

The protein's association with Intellectual developmental disorder, autosomal dominant 50, with behavioral abnormalities highlights its potential as a target for therapeutic intervention. Understanding the role of N-alpha-acetyltransferase 15 could open doors to potential therapeutic strategies.